White Oak Allergy Shots (SCIT)
White oak (Quercus alba) is the only US oak species with a formally named WHO/IUIS allergen — Que a 1 — and the species used in the Jeong 2016 ImmunoCAP inhibition study that produced the 77.4–81.5% Bet v 1 inhibition figure underpinning all birch-oak cross-reactivity claims.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
White Oakis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
White Oak Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to white oak — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of white oak allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of white oak immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of white oak extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for white oak allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing white oak extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription white oak immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat white oak allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is White Oak?
The biology, taxonomy, and clinical fingerprint of White Oak — the foundation of how SCIT targets it.
Quercus alba — white oak — is the reference species for oak allergenicity in the US, carrying the only WHO/IUIS-named Quercus allergen (Que a 1) and used in the key birch-oak cross-reactivity inhibition assay (Jeong 2016) that established the 77.4–81.5% Bet v 1 IgE inhibition figure cited across the field.
- Scientific name
- Quercus alba L.
- Family
- FagaceaeBeech family
- Type
- Deciduous tree pollen
- Native to
- Eastern United States — Maine to Florida, west to Texas and Minnesota (USDA PLANTS)
- Allergen proteins
- Que a 1 (major) — PR-10/Bet v 1 homolog, ~17 kDa, 72–95% sequence identity with Bet v 1 (WHO/IUIS allergen.org)Quercus profilin — pan-allergenQuercus Ca-binding proteins — polcalcinsNOTE: Que a 1 is the ONLY formally named IUIS allergen for any US Quercus species; all other North American oaks (live oak, post oak, red oak, black oak) lack named allergens at WHO/IUIS as of May 2026
- Particle size
- 25–35 μm
- Avoidance difficulty
- Nearly impossible
How White Oak Allergy Presents
Symptoms by body system — useful for distinguishing White Oak sensitivity from overlapping allergies and infections.
Respiratory
- Sneezing and profuse clear rhinorrhea during March–May white oak pollen season across the eastern US
- Nasal congestion and itching on high-count days — white oak contributes substantially to the >1,000 grains/m³ peaks common across the Mid-Atlantic and Southeast
- Allergic asthma exacerbations — bronchospasm and wheezing in sensitized asthmatic patients during peak weeks
- Persistent post-nasal drip and cough during the 6–8 week oak season
- Worsening symptoms on warm, dry, windy days when white oak catkins reach peak dehiscence
Ocular
- Bilateral eye itching and watering during the March–May white oak season
- Conjunctival redness and swelling persisting through high-pollen weeks
- Morning eyelid puffiness and crusting from overnight pollen exposure
- Photophobia and reduced visual comfort during severe allergic conjunctivitis episodes
Dermal
- Oral allergy syndrome (OAS) to raw apple, hazelnut kernel, peach, or cherry via Que a 1 / Bet v 1 PR-10 cross-reactivity — less common in white-oak monosensitized patients than in birch-primary patients
- Contact urticaria from direct oak pollen contact in highly sensitized individuals
- Eczema flares in spring coinciding with peak oak pollen counts
Systemic
- Fatigue and impaired concentration during the extended March–May season
- Sleep disruption from nighttime nasal congestion during high-pollen weeks
- Reduced outdoor activity tolerance during prime spring season in the eastern US
- Cumulative quality-of-life burden from one of the longest sustained tree-pollen exposures in North America
White oak is the only US oak with a formally named WHO/IUIS allergen — Que a 1 — and the Jeong 2016 inhibition data tell us that white oak extract neutralizes about 80% of birch IgE binding. That's why a birch-anchored SCIT mix gives my white-oak patients real symptom relief even without a dedicated oak RCT: we're desensitizing the same PR-10 epitope from the birch side.
When & Where White Oak Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late March through April across the eastern US; later (April–May) in northern portions of range· ~6–8 weeks; later-starting season than live oak (which peaks February–April in the Gulf states)
US Exposure Map
11 high-intensity statesExposure intensity by state (text version)
- ME:
- Moderate
- VT:
- Moderate
- NH:
- Moderate
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Moderate
- MI:
- Moderate
- NY:
- Moderate
- MA:
- Moderate
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Moderate
- IN:
- High
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- Moderate
- RI:
- Moderate
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Moderate
- KY:
- High
- WV:
- High
- VA:
- High
- MD:
- High
- DE:
- High
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Moderate
- TN:
- High
- NC:
- High
- SC:
- Moderate
- OK:
- Low
- LA:
- Low
- MS:
- Moderate
- AL:
- Moderate
- GA:
- Moderate
- TX:
- Low
- FL:
- Moderate
- AK:
- Low
- HI:
- Low
What White Oak Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
White oak Que a 1 shares 72–95% amino-acid identity with birch Bet v 1, and a white oak pollen extract inhibits 77.4–81.5% of Bet v 1 IgE binding in ImmunoCAP inhibition assays (Jeong 2016) — the strongest published quantitative measure of birch-oak cross-reactivity. This bidirectional inhibition is the molecular basis for Itulazax TT-04 oak-season cross-protection in birch-sensitized patients.
Within-genus; no named Q. virginiana allergen; cross-reactivity inferred from Que a 1 homology
Que a 1 / Bet v 1 — 77.4–81.5% Bet v 1 IgE inhibition (Jeong et al., JKMS 2016)
Birch SCIT cross-protects against white oak season per Itulazax TT-04 secondary endpoint
Mal d 1 PR-10 OAS — less prominent with white-oak monosensitization than birch
White Oak PR-10 Oral Allergy Syndrome
White oak-sensitized patients may experience oral allergy syndrome to the same raw foods as birch-allergic patients — apple, hazelnut kernel, peach, cherry, carrot — via Que a 1 / Bet v 1 PR-10 cross-reactivity. However, OAS is considerably less common and less severe in white-oak-monosensitized patients than in those with primary birch sensitization. If your OAS is prominent, concurrent birch (Bet v 1) sensitization is likely a major contributor. A board-certified allergist can run component-resolved testing to determine the primary PR-10 driver. See the white birch page for the complete PR-10 OAS food table.
Is SCIT Right for Your White Oak Allergy?
Answer five questions to assess whether white oak SCIT or a birch-anchored oak cross-protection approach is right for your spring tree allergy.
How severe are your spring oak-season symptoms (March–May)?
The White Oak SCIT Protocol
White oak SCIT uses non-standardized Q. alba extract — the reference species for Quercus allergenicity in the US and the only oak with a formally named IUIS allergen. A birch-anchored Fagales mix often provides equivalent oak cross-protection without a dedicated oak-specific extract.
Injections begin at 1:100,000 w/v — Curex's conservative starting dilution — and increase incrementally. Eastern US patients should start build-up in summer to avoid co-exposure during the March–May oak season. With Curex, eligible patients run this build-up at home — the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and a 30-minute observation follows each injection. Patients with active PR-10 OAS to raw apple or hazelnut should disclose this — the build-up rate may be adjusted accordingly.
Ongoing maintenance sustains Que a 1 tolerance and Fagales PR-10 cross-reactive immunity. The Itulazax TT-04 oak-season secondary endpoint confirms that Bet v 1 / Que a 1 cross-reactive immunotherapy produces meaningful oak-season symptom reduction — and vice versa, white oak SCIT should cross-protect against the birch season.
Lasting benefit of 7–12+ years is expected with full course completion. Because white oak season is long and high-intensity in the eastern US, patients who complete the full course tend to have sustained and durable relief.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for White Oak SCIT
White oak SCIT has no species-specific RCT. All clinical evidence derives from the birch-homologous family evidence base — particularly the Itulazax TT-04 oak-season secondary endpoint and the Jeong 2016 inhibition assay that first quantified the degree of birch-oak IgE cross-reactivity.
- Bet v 1 IgE inhibition by white oak pollen extract79%Jeong et al., J Korean Med Sci 2016 (ImmunoCAP inhibition — 77.4–81.5% range; N=20 birch-allergic patients)
- Oak-season symptom reduction (birch-homologous immunotherapy)62%Itulazax TT-04 secondary endpoint — oak season; ALK/EMA 2019, N=634 birch-sensitized adults
No SCIT RCT has been conducted specifically in Q. alba or Q. rubra. The Jeong 2016 inhibition assay establishes that white oak extract and birch extract inhibit each other's IgE binding by 77–82%, providing the molecular rationale for bidirectional cross-protection. The Itulazax TT-04 oak-season secondary endpoint confirms this cross-protection is clinically meaningful — birch-sensitized patients on birch-homologous immunotherapy show real symptom reduction during oak season. All efficacy estimates for white oak SCIT are extrapolated from this family-level evidence.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
White Oak SCIT Side Effects
White oak SCIT side effects follow the standard inhalant SCIT profile. A summer build-up start is strongly preferred for eastern US patients to minimize the reactivity increase that occurs when build-up doses coincide with active March–May oak pollen exposure.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Expected during build-up; resolves within 24 hours | Rate 30–50% | Mild |
Injection-site itching Ice and pre-treatment antihistamine recommended on injection days | Rate 20–40% | Mild |
Large local reaction (>25 mm) Higher during active pollen season; does not reliably predict systemic risk | Rate 5–10% | Moderate |
Persistent redness and warmth Resolves within 24 hours in most cases | Rate 10–20% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis/conjunctivitis flare Sneezing or eye watering within minutes to 1 hour; antihistamine responsive | Rate 0.5–1% | Mild |
Urticaria Generalized hives; managed with antihistamines ± epinephrine | Rate 0.1–0.5% | Moderate |
Bronchospasm Higher risk in asthmatic patients; spirometry recommended before starting SCIT | Rate 0.1–0.3% | Moderate |
Anaphylaxis Rare at properly titrated doses with 30-minute observation; a prescribed epinephrine auto-injector is confirmed on hand and dosing is supervised live in the Virtual Shot Room | Rate <0.01% | Severe |
A 30-minute observation accompanies every white oak SCIT dose. With Curex, eligible patients self-administer at home — the serum is sterile-compounded to USP <797>, a prescribed epinephrine auto-injector is confirmed on hand, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room. Eastern US patients with active spring oak symptoms should ideally complete build-up before March to avoid elevated reactivity at peak exposure, and active uncontrolled asthma should be stabilized before initiating SCIT.
SCIT vs Alternatives for White Oak
White-oak-allergic patients have four main treatment options: Fagales-anchored SCIT (often birch-anchored with oak cross-protection), at-home sublingual drops, avoidance, and daily seasonal medications.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | High — birch-homologous Phase 3 evidence (Itulazax TT-04) + Jeong 2016 inhibition data | Moderate — no FDA-approved oak SLIT tablet; off-label drops available | Low — Q. alba produces extreme pollen volumes; outdoor avoidance near impossible at peak | Moderate — antihistamines + nasal corticosteroids for mild-to-moderate symptoms |
| 5-yr cost | $3,500–$15,000 over 5 years | Varies by provider; sold as a general sublingual modality, not Curex's product | Low — HEPA, pollen masks, air purifiers | $500–$2,000 over 5 years |
| Duration | 3–5 year course | 3–5 year course | Indefinite — no tolerance change | Indefinite — seasonal use |
| Convenience | At-home weekly self-injection; summer start preferred | Daily at-home — no clinic required | High inconvenience during spring | High convenience |
| Safety | Excellent — USP <797> serum, Virtual Shot Room–supervised dosing, 30-min self-observation | Favorable — no systemic anaphylaxis in EU trials | Safe | Generally safe |
| Lasting effect | 7–12+ years after completion | Emerging — less durability data vs SCIT | None — symptoms return each March | None — must take every season |
SCITBest
SLIT
Avoidance
Medications
SCIT — anchored to birch or white oak via the shared Que a 1 / Bet v 1 PR-10 epitope — is the only therapy with evidence for lasting tolerance modification. Curex now delivers this disease-modifying SCIT at home with pricing confirmed in a current program quote — a Fagales PR-10 serum sterile-compounded to USP <797>, weekly self-injection with the first injection from each new vial or concentration supervised live in the Virtual Shot Room, and a prescribed epinephrine auto-injector confirmed on hand under board-certified allergist oversight.
What White Oak SCIT Actually Costs
White oak SCIT is covered by most major US insurers under standard allergy immunotherapy benefits. Because Que a 1 is the named allergen for clinical documentation, component-resolved testing can support insurance authorization with specific allergen protein documentation. Pre-authorization is recommended; oak is typically billed as part of a multi-tree Eastern mix. Curex at-home IgE testing identifies specific white oak sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your white oak allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
White Oak SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
The WHO/IUIS Allergen Nomenclature process names allergens from specific species only after sufficient molecular characterization and published evidence of clinical relevance. Q. alba was characterized first among US oaks — Que a 1 was isolated, sequenced, and shown to be an IgE-binding PR-10 protein — earning it formal IUIS designation. Other clinically important US oaks (Q. rubra red oak, Q. virginiana live oak, Q. stellata post oak, Q. velutina black oak) have not undergone equivalent molecular characterization. This is an evidence gap in the IUIS catalogue: the clinical importance of these species is well-established by skin-prick test data, but the underlying proteins remain formally unnamed. For clinical practice, allergists treat the genus-level cross-reactivity rather than species-specific allergens — and Que a 1 from Q. alba is the reference protein for that cross-reactivity.
Yes, in most cases. Intra-genus Quercus cross-reactivity via Que a 1 PR-10 is very high — all oaks express homologous PR-10 proteins that share the same core epitope with Que a 1 from Q. alba. ImmunoCAP inhibition studies confirm that Q. alba extract inhibits IgE binding from patients sensitized to multiple Quercus species. An oak-mix SCIT formulation (Q. alba + Q. rubra) provides even broader within-genus coverage. In practice, most allergists prescribe oak as part of a multi-species Eastern tree mix rather than a single-species extract, and the cross-protection covers the full suite of Quercus species in a patient's regional environment.
White oak (Q. alba) is a deciduous tree with a March–May pollen season in the eastern US, and carries the only formally named WHO/IUIS allergen for any US Quercus species (Que a 1). Live oak (Q. virginiana) is an evergreen Gulf-coast oak with a distinct February–April pollen season — earlier and regionally different. Live oak has no named WHO/IUIS allergen as of May 2026, and its molecular allergenicity is inferred from Que a 1 homology rather than directly characterized. In clinical practice, patients in Gulf-coast states (Texas, Louisiana, Mississippi, Alabama, Georgia, Florida) may experience two distinct oak allergy seasons — live oak in February–April and deciduous oaks in March–May — requiring careful seasonal attribution during the evaluation.
Yes. Component-resolved testing for Que a 1 alongside Bet v 1 (birch) and Que a 1 (oak) can determine whether you are oak-monosensitized (uncommon) or broadly Fagales PR-10-sensitized (typical). Most patients who test positive to whole oak extract by skin prick test have co-existing birch sensitization via shared Bet v 1 / Que a 1 PR-10 epitopes. If Bet v 1 is your primary sensitizer, a birch-anchored SCIT mix with cross-protection to oak may be optimal. If Que a 1 is high and Bet v 1 is low, oak may be your primary driver and should anchor the extract. This distinction can improve the targeting of your immunotherapy regimen, though in practice many allergists simply include both birch and oak in an Eastern tree mix.
Yes, SCIT for white oak allergy is appropriate for asthmatic patients — but with important preconditions. Active, poorly controlled asthma is a relative contraindication to initiating SCIT, because the risk of systemic reactions and bronchospasm is elevated. Before starting white oak SCIT, a board-certified allergist will assess your current asthma control (typically with spirometry or peak flow measurement) and optimize your controller medications if needed. Once asthma is well-controlled, SCIT can proceed — and there is evidence that allergen immunotherapy for tree pollen may reduce asthma exacerbation frequency during pollen season. A large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found a systemic reaction rate of just 0.16% per patient across 23,614 patients and 2,021,600 injections, with no fatalities — lower than the 3%–14% typically seen with office-based shots. The mandatory 30-minute post-injection observation period is especially important for asthmatic patients.
White oak pollen season typically runs from late March through May across the eastern US — roughly 6–8 weeks of sustained high airborne pollen at counts that can exceed 1,000 grains per cubic meter in the Southeast and Mid-Atlantic. This extended high-exposure window is clinically important for SCIT timing: starting build-up during active oak season increases the risk of larger local reactions and systemic reactions at each dose increment. The preferred approach is to initiate build-up in summer (June–August), reach maintenance dose before the following March, and then maintain through the full spring season. Discuss your schedule with a board-certified allergist at least 6 months before the next oak season.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.